Generally, following local therapy for pure DCIS, 5 years of endocrine therapy with either tamoxifen or an aromatase inhibitor is recommended for ER- and/or PR-positive patients to reduce the risk of ipsilateral breast events and contralateral breast cancer. This evidence concerns the gene ESR1 and ductal breast carcinoma in situ.